Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic

被引:39
|
作者
Mellinger, Jessica L. [1 ]
Winder, Gerald Scott [2 ,7 ]
Fernandez, Anne C. [2 ,3 ]
Klevering, Kristin [3 ,4 ]
Johnson, Amanda [1 ]
Asefah, Haila [1 ]
Figueroa, Mary [5 ]
Buchanan, Jack [6 ]
Blow, Fred [2 ,3 ]
Lok, Anna S. F. [1 ]
机构
[1] Michigan Med, Dept Internal Med, Ann Arbor, MI USA
[2] Michigan Med, Dept Psychiat, Ann Arbor, MI USA
[3] Univ Michigan, Addict Treatment Serv, Michigan Med, Ann Arbor, MI 48109 USA
[4] Michigan Med, Dept Social Work, Ann Arbor, MI USA
[5] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Med Sch, Ann Arbor, MI USA
[7] Michigan Med, Dept Surg, Ann Arbor, MI USA
关键词
Alcoholic cirrhosis; Psychiatry; Addiction; Alcohol use disorder; Quality; VALIDATION; DISORDER;
D O I
10.1016/j.jsat.2021.108396
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Alcohol cessation improves mortality in alcohol-associated liver disease (ALD), but access to treatment is limited. To address this gap, implementation and early feasibility and outcomes of a multidisciplinary ALD clinic are described. Methods: The clinic comprised a hepatologist, psychiatrist, psychologist, nurse, and social worker. Patients included those with alcohol-associated cirrhosis or acute alcoholic hepatitis who were not in the transplant evaluation process, who had less than 6 months' sobriety and willingness to engage in alcohol use treatment. Psychosocial metrics in addition to routine hepatic function labs were collected. Treatment plans were tailored based on patient preferences and needs after multidisciplinary discussion. Results: 89 patients were referred from both inpatient and outpatient settings, with 51 seen during the initial year. 38 remained active in clinic (4 died, 6 discharged, 3 moved to transplant clinic). 55% were women, 88% were white, 61% had private insurance. 49% had alcoholic hepatitis. 71% were decompensated. 80% had severe alcohol use disorder (AUD) and 84% had at least 1 comorbid psychiatric or substance use disorder. 63% chose one-on-one AUD treatment, 57% were prescribed relapse prevention medications. Mean MELD-Na score improved from baseline of 14 (SD 6.6) to 11.3 at 6 months (p=0.01). Hospital utilization significantly declined when comparing 6 months before to 6 months after initial visit (emergency department visits: 0.51 to 0.20 per person-month; inpatient admission: 0.34 to 0.14 per person-month; (beta=-0.89, 95% CI-1.18 to -0.60). Conclusions: A multidisciplinary ALD clinic was feasible with encouraging early outcomes. Further research should explore ways to expand this model and increase clinic capacity.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Gut Microbiome and Alcohol-associated Liver Disease
    Philips, Cyriac A.
    Schnabl, Bernd
    Bajaj, Jasmohan S.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (05) : 1349 - 1359
  • [32] Inflammation in alcohol-associated liver disease progression
    Lotersztajn, Sophie
    Riva, Antonio
    Wang, Sai
    Dooley, Steven
    Chokshi, Shilpa
    Gao, Bin
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (01): : 58 - 66
  • [33] Complement System in Alcohol-Associated Liver Disease
    Santiesteban-Lores, Lazara Elena
    Carneiro, Milena Carvalho
    Isaac, Lourdes
    Bavia, Lorena
    IMMUNOLOGY LETTERS, 2021, 236 : 37 - 50
  • [34] Advancements in the Alcohol-Associated Liver Disease Model
    Zhu, Lin
    Li, Hai-Di
    Xu, Jie-Jie
    Li, Juan-Juan
    Cheng, Miao
    Meng, Xiao-Ming
    Huang, Cheng
    Li, Jun
    BIOMOLECULES, 2022, 12 (08)
  • [35] The role of SELENOF in alcohol-associated liver disease
    Boedeker, K.
    Qiu., W.
    ALCOHOL, 2024, 121
  • [36] Activation of HSCs in alcohol-associated liver disease
    Kisseleva, T.
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 47 : 83 - 83
  • [37] Therapeutic Pipeline in Alcohol-Associated Liver Disease
    Thakral, Nimish
    Deutsch-Link, Sasha
    Singal, Ashwani K.
    SEMINARS IN LIVER DISEASE, 2023, 43 (01) : 60 - 76
  • [38] Alcohol-associated liver disease: Epidemiology and management
    Hernandez-Evole, Helena
    Jimenez-Esquivel, Natalia
    Pose, Elisa
    Bataller, Ram on
    ANNALS OF HEPATOLOGY, 2024, 29 (01)
  • [39] Alcohol-Associated Liver Disease: Treatment and Prevention
    Singal, Ashwani K.
    CLINICS IN LIVER DISEASE, 2024, 28 (04)
  • [40] OPTIMIZING ALCOHOL-ASSOCIATED LIVER DISEASE MANAGEMENT IN A NOVEL CO-LOCATED MULTI-DISCIPLINARY CLINIC.
    Benjamin, Chanelle
    Musto, Jessica
    Brown, Randall
    German, Margarita N.
    GASTROENTEROLOGY, 2024, 166 (05) : S1680 - S1680